The renal protective effect of angiotensin receptor blockers depends on intra-individual response variation in multiple risk markers

Biomarkers and personalized therapy in chronic kidney diseases

(2014) Francesco Paolo Schena   EXPERT OPINION ON INVESTIGATIONAL DRUGS

A novel approach for establishing cardiovascular drug efficacy

(2014) Hiddo. J. Lambers Heerspink et al.   NATURE REVIEWS DRUG DISCOVERY

The Importance of Short-Term Off-Target Effects in Estimating the Long-Term Renal and Cardiovascular Protection of Angiotensin Receptor Blockers

(2013) P A Smink et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

A prediction of the renal and cardiovascular efficacy of aliskiren in ALTITUDE using short-term changes in multiple risk markers

(2013) PA Smink et al.   European Journal of Preventive Cardiology

An initial reduction in serum uric acid during angiotensin receptor blocker treatment is associated with cardiovascular protection

(2012) Paul A. Smink et al.   JOURNAL OF HYPERTENSION

Antihypertensive Therapy in Diabetes: The Legacy Effect and RAAS Blockade

(2011) Massimo Volpe et al.   CURRENT HYPERTENSION REPORTS

Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: a post hoc analysis of the combined RENAAL and IDNT trials

(2011) F. A. Holtkamp et al.   EUROPEAN HEART JOURNAL

Joint analysis of multiple biomarkers for identifying type 2 diabetes in middle-aged and older Chinese: a cross-sectional study

(2011) H. Wu et al.   BMJ Open

Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial

(2010) Y. Miao et al.   DIABETOLOGIA

Development of a Type 2 Diabetes Risk Model From a Panel of Serum Biomarkers From the Inter99 Cohort

(2009) J. A. Kolberg et al.   DIABETES CARE

The evolving story of the RAAS in hypertension, diabetes and CV disease - moving from macrovascular to microvascular targets

(2009) Ulrike Muscha Steckelings et al.   FUNDAMENTAL & CLINICAL PHARMACOLOGY

Supramaximal Dose of Candesartan in Proteinuric Renal Disease

(2009) E. Burgess et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Effects of Dietary Sodium and Hydrochlorothiazide on the Antiproteinuric Efficacy of Losartan

(2008) L. Vogt et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

The effect of losartan on hemoglobin concentration and renal outcome in diabetic nephropathy of type 2 diabetes

(2007) A. Mohanram et al.   KIDNEY INTERNATIONAL